Oral glucose tolerance test performance in olanzapine-treated schizophrenia-spectrum patients is predicted by BMI and triglycerides but not olanzapine dose or duration.

Abstract

OBJECTIVE:

Olanzapine, an atypical antipsychotic, is associated with glucoregulatory abnormalities, but the nature of this link is not fully elucidated. This is the first olanzapine oral glucose tolerance test (oGTT) study to consider treatment dose and duration, and to compare complementary indices respectively assessing insulin sensitivity (Matsuda index) and resistance (homeostasis model assessment).

METHODS:

Body mass index (BMI), body composition, plasma lipids, and oGTT were measured in olanzapine-treated nondiabetic patients with DSM-IV-TR diagnosis of schizophrenia or schizoaffective disorder (n = 35).

RESULTS:

While only one previously undiagnosed participant met diabetes criteria based on fasting plasma glucose alone (≥126 mg/dL), seven were diagnosed with oGTT (2-hr plasma glucose ≥200 mg/dL). Multiple regression analyses revealed that the Matsuda index correlated with BMI (p < 0.0001) and plasma triglycerides (p = 0.01), but not with age, olanzapine dose, olanzapine treatment duration, or plasma cholesterol. Homeostasis model assessment and fasting plasma glucose correlated with triglycerides only (p < 0.0001 for both).

CONCLUSIONS:

Our data suggest that BMI and triglycerides may be implicated in olanzapine-related glucoregulatory abnormalities. The lack of correlation between glucoregulatory abnormalities and olanzapine dose or treatment duration suggests preexisting metabolic disturbances and/or disturbances arising early in the course of treatment. Clinicians prescribing antipsychotics should consider oGTT, especially in patients with obesity and/or hypertriglyceridemia.

• Authors: Jeffrey Guina, Sayon Roy, Ankur Gupta, Daniel D Langleben, Igor Elman
• Journal: Human psychopharmacology (Hum Psychopharmacol) Vol. 32 Issue 4 (07 2017) ISSN: 1099-1077 [Electronic] England
• PMID: 28573760 (Publication Type: Journal Article)
• Copyright: Copyright © 2017 John Wiley & Sons, Ltd.

Chemical References

• Antipsychotic Agents
• Blood Glucose
• Triglycerides
• Benzodiazepines
• Olanzapine

Topics

• Adult
• Aged
• Antipsychotic Agents (adverse effects, therapeutic use)
• Benzodiazepines (adverse effects, therapeutic use)
• Blood Glucose (drug effects)
• Body Mass Index
• Dose-Response Relationship, Drug
• Female
• Glucose Tolerance Test
• Homeostasis (drug effects)
• Humans
• Insulin Resistance
• Male
• Middle Aged
• Olanzapine
• Psychotic Disorders (drug therapy, metabolism)
• Regression Analysis
• Schizophrenia (drug therapy, metabolism)
• Triglycerides (blood)